Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.

NCT00003078 · ClinicalTrials.gov registry record · Phase 3

Radiation Therapy With or Without Cisplatin or Fluorouracil in Treating Patients With Cancer of the Cervix

A Phase 3 study of Cervical Cancer, sponsored by Gynecologic Oncology Group.

Completed
Registry status
Phase 3
Development phase
870
Enrollment target
20
Study locations

NCT00003078 is a Phase 3 study of Cervical Cancer that has completed, run by Gynecologic Oncology Group. The registered enrollment target is 870 participants, above the 564-participant average among 144 other Cervical Cancer trials with a reported enrollment target (54% higher). The trial reports 20 study locations across 12 states.

View on ClinicalTrials.gov ↗

View your shortlist →

The verdict

NCT00003078, a Phase 3 study of Cervical Cancer, has completed, sponsored by Gynecologic Oncology Group.

COMPLETED
Registry status
Phase 3
Development phase
870 participants
Enrollment target
20
Study locations

Study Summary

RATIONALE: Radiation therapy uses high-energy x-rays to damage tumor cells. Drugs used in chemotherapy use different ways to stop tumor cells from dividing so they stop growing or die. Combining radiation therapy and chemotherapy may kill more tumor cells. It is not known whether receiving radiation therapy plus cisplatin is more effective than receiving radiation therapy plus fluorouracil in treating patients with cancer of the cervix. PURPOSE: Randomized phase III trial to compare the effectiveness of radiation therapy plus cisplatin or fluorouracil in treating patients with primary stage IIB, stage IIIB, or stage IVA cancer of the cervix.

Conditions Studied

Interventions

  • DRUG cisplatin
  • DRUG fluorouracil
  • RADIATION radiation therapy
  • RADIATION brachytherapy

Study Locations (20)

California

  • USC/Norris Comprehensive Cancer Center - Los Angeles
  • Jonsson Comprehensive Cancer Center, UCLA - Los Angeles
  • Chao Family Comprehensive Cancer Center - Orange
  • Women's Cancer Center - Palo Alto

Illinois

  • Rush-Presbyterian-St. Luke's Medical Center - Chicago
  • University of Chicago Cancer Research Center - Chicago
  • CCOP - Central Illinois - Decatur
  • CCOP - Evanston - Evanston

District of Columbia

  • Vincent T. Lombardi Cancer Research Center, Georgetown University - Washington D.C.
  • Walter Reed Army Medical Center - Washington D.C.

Florida

  • Fred J. Woods Radiation Therapy Center/St. Joseph's Cancer Institute - Tampa
  • H. Lee Moffitt Cancer Center and Research Institute - Tampa

Alabama

  • University of Alabama Comprehensive Cancer Center - Birmingham

Arizona

  • CCOP - Greater Phoenix - Phoenix

Colorado

  • University of Colorado Cancer Center - Denver

Georgia

  • Emory University Hospital - Atlanta - Atlanta

Trial Details

FieldValue
Enrollment Target 870 participants
Start Date 1997-10
Phase Phase 3

Sponsor

Gynecologic Oncology Group

154 total trials

What the Registry Record Tells You About NCT00003078

The ClinicalTrials.gov registry entry for NCT00003078 describes a study currently listed as completed, categorized as Phase 3. The registered enrollment target is 870 participants, a figure that helps gauge the scale of data the investigators plan to collect, above the 564-participant average among 144 other Cervical Cancer trials with a reported enrollment target (54% higher). The listed sponsor is Gynecologic Oncology Group, which has 154 total studies on file at ClinicalTrials.gov.

The record links to 1 condition, with Cervical Cancer appearing as the primary indexed condition, and to 4 interventions - of which cisplatin is the first listed.

NCT00003078 reports 20 study locations spanning 12 distinct geographic areas - top geographies include California, Illinois, District of Columbia.

Frequently Asked Questions

What is clinical trial NCT00003078 about?

NCT00003078 is a clinical study titled "Radiation Therapy With or Without Cisplatin or Fluorouracil in Treating Patients With Cancer of the Cervix". RATIONALE: Radiation therapy uses high-energy x-rays to damage tumor cells. Drugs used in chemotherapy use different ways to stop tumor cells from dividing so they stop growing or die. Combining radiation therapy and chemotherapy may kill more tumor cells. It is not known whether receiving radiation...

What is the current status of trial NCT00003078?

This trial is currently completed. It is a Phase 3 study. The enrollment target is 870 participants. The study started on 1997-10.

What conditions does trial NCT00003078 study?

This clinical trial studies the following conditions: Cervical Cancer.

What interventions are being tested in trial NCT00003078?

The interventions under investigation include: cisplatin (DRUG), fluorouracil (DRUG), radiation therapy (RADIATION), brachytherapy (RADIATION).

Who is sponsoring clinical trial NCT00003078?

This trial is sponsored by Gynecologic Oncology Group, which has 154 total clinical trials registered on ClinicalTrials.gov.

Where is trial NCT00003078 being conducted?

This trial has 20 study locations across Alabama, Arizona, California, Colorado, District of Columbia. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.

Similar trials for Cervical Cancer

Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.

Data sourced from official public datasets. See our methodology for details. Retrieved and formatted by PlainTrial Editorial

Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.